NextCell Pharma
NextCell's CSO Appointed to the Board of ATMP Sweden
ATMP Sweden is a key organization for the development and implementation of Advanced Therapy Medicinal Products (ATMPs) in Sweden. By bringing together academia, industry, and healthcare, the organization works to strengthen Sweden's position as a leader in cell and gene therapies. ATMP Sweden serves as a platform for collaboration, knowledge sharing, and strategic development and plays a crucial role in realizing the potential of advanced therapies within the Swedish healthcare system.
Dr. Lindsay Davies is already a well-established voice in the international cell and gene therapy field. She was recently nominated as Vice President Elect for Europe within the International Society for Cell and Gene Therapy (ISCT), highlighting her influence and leadership on a global scale. As an active member of ISCT's global industry committee, she has championed key issues related to quality and safety in the development of cell and gene therapies (CGT) and has published scientific articles in the society's journal Cytotherapy.
"Representing NextCell on the board of ATMP Sweden is an honour and a valuable opportunity to contribute to the strategic development of advanced therapies in Sweden. I look forward to working alongside other leading stakeholders in the field to collectively strengthen Sweden's position in this rapidly growing industry," says Dr. Lindsay Davies.
NextCell Pharma is already an active player in the ATMP space through the development of ProTrans, a cell therapy candidate currently undergoing Phase II trials for the treatment of type 1 diabetes. With Lindsay Davies now on the board of ATMP Sweden, the company gains further opportunities to contribute to the national strategy for advanced therapies.
Datum | 2025-03-28, kl 10:00 |
Källa | Cision |
